Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Circulating MicroRNAs Associated with Type 2 Diabetes

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes…. 

Advertisement

Francisco J. Ortega, Ph.D., and colleagues from the Institut d'Investagacio Biomedica de Girona in Spain studied circulating miRNA in 12 men, six of whom had normal glucose tolerance and the other six who had type 2 diabetes. The association of 10 circulating miRNAs with type 2 diabetes was also verified cross-sectionally in another sample of 45 men with normal glucose tolerance and 48 men with type 2 diabetes. A longitudinal validation was carried out in 35 patients with type 2 diabetes in a randomized, three month long metformin trial. Furthermore, circulating miRNAs were studied in seven healthy participants before and after a six hour hyperinsulinemic-euglycemic clamp and insulin plus intralipid/heparin infusion.

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes. They found that miR-140-5p and miR-423-5p independently accounted for 49.5% of fasting glucose variance after controlling for confounders. These two specific miRNAs along with miR-195 and miR-126 were specific for type 2 diabetes with 89.2% accuracy. Significant reduction in fasting glucose, glycated hemoglobin, and changes in circulating miR-192, miR-140-5p, and miR-22 were seen with metformin but not placebo. Reduction in miR-222 was seen with insulin infusion during clamp, while increases in circulating miR-222 and miR-140-5p were seen with the intralipid/heparin mixture. These results show that there is a close association between circulating miRNAs and type 2 diabetes.

Practice Pearls:
  • Levels of circulating miRNAs vary with insulin action
  • There is an association between circulating miRNAs and type 2 diabetes as they may play a potentially important role in insulin sensitivity

"Circulating MicroRNAs Linked to Type 2 Diabetes."  http://www.ncbi.nlm.nih.gov/pubmed/24478399

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75